GB201703063D0 - Stabilized antibody protein solutions - Google Patents

Stabilized antibody protein solutions

Info

Publication number
GB201703063D0
GB201703063D0 GBGB1703063.6A GB201703063A GB201703063D0 GB 201703063 D0 GB201703063 D0 GB 201703063D0 GB 201703063 A GB201703063 A GB 201703063A GB 201703063 D0 GB201703063 D0 GB 201703063D0
Authority
GB
United Kingdom
Prior art keywords
antibody protein
protein solutions
stabilized antibody
stabilized
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1703063.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arecor Ltd
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arecor Ltd filed Critical Arecor Ltd
Priority to GBGB1703063.6A priority Critical patent/GB201703063D0/en
Publication of GB201703063D0 publication Critical patent/GB201703063D0/en
Priority to EP18708465.2A priority patent/EP3585820A1/en
Priority to JP2019546211A priority patent/JP7278952B2/ja
Priority to EP23196633.4A priority patent/EP4289443A3/en
Priority to PCT/GB2018/050480 priority patent/WO2018154319A1/en
Priority to US16/487,999 priority patent/US20200023062A1/en
Priority to JP2022208841A priority patent/JP2023052088A/ja
Priority to US18/111,017 priority patent/US20230277453A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
GBGB1703063.6A 2017-02-24 2017-02-24 Stabilized antibody protein solutions Ceased GB201703063D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB1703063.6A GB201703063D0 (en) 2017-02-24 2017-02-24 Stabilized antibody protein solutions
EP18708465.2A EP3585820A1 (en) 2017-02-24 2018-02-23 Stabilized antibody protein solutions
JP2019546211A JP7278952B2 (ja) 2017-02-24 2018-02-23 安定化された抗体タンパク質溶液
EP23196633.4A EP4289443A3 (en) 2017-02-24 2018-02-23 Stabilized antibody protein solutions
PCT/GB2018/050480 WO2018154319A1 (en) 2017-02-24 2018-02-23 Stabilized antibody protein solutions
US16/487,999 US20200023062A1 (en) 2017-02-24 2018-02-23 Stabilized antibody protein solutions
JP2022208841A JP2023052088A (ja) 2017-02-24 2022-12-26 安定化された抗体タンパク質溶液
US18/111,017 US20230277453A1 (en) 2017-02-24 2023-02-17 Stabilized antibody protein solutions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1703063.6A GB201703063D0 (en) 2017-02-24 2017-02-24 Stabilized antibody protein solutions

Publications (1)

Publication Number Publication Date
GB201703063D0 true GB201703063D0 (en) 2017-04-12

Family

ID=58544083

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1703063.6A Ceased GB201703063D0 (en) 2017-02-24 2017-02-24 Stabilized antibody protein solutions

Country Status (5)

Country Link
US (1) US20200023062A1 (https=)
EP (2) EP4289443A3 (https=)
JP (2) JP7278952B2 (https=)
GB (1) GB201703063D0 (https=)
WO (1) WO2018154319A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
US20230041240A1 (en) * 2020-01-30 2023-02-09 Leukocare Ag Reduction of Adsorption
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition
CN121002123A (zh) 2023-03-28 2025-11-21 住友化学株式会社 树脂组合物、成型体及树脂组合物的制造方法
CN117007791B (zh) * 2023-07-18 2024-08-09 广州市进德生物科技有限公司 一种辣根过氧化物酶偶联物稀释保存液

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
AU2006295340B2 (en) * 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
EP3372241A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition

Also Published As

Publication number Publication date
WO2018154319A1 (en) 2018-08-30
EP4289443A2 (en) 2023-12-13
EP4289443A3 (en) 2024-02-28
US20200023062A1 (en) 2020-01-23
JP2020508333A (ja) 2020-03-19
JP2023052088A (ja) 2023-04-11
EP3585820A1 (en) 2020-01-01
JP7278952B2 (ja) 2023-05-22

Similar Documents

Publication Publication Date Title
ZA201905966B (en) Anti-lag3 antibodies
IL268517A (en) Anti-tigit antibodies
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
SG11202000660QA (en) Anti-tigit antibodies
ZA202002141B (en) Anti-transthyretin antibodies
PT3625259T (pt) Anticorpos anti-sirpalfa
GB201709808D0 (en) Antibodies
GB201703063D0 (en) Stabilized antibody protein solutions
GB201601073D0 (en) Antibodies
SG10201914130VA (en) GARP-TGF-β ANTIBODIES
GB201703062D0 (en) Stabilized antibody protein solutions
ZA202103456B (en) Anti-alpha-synuclein antibodies
GB201720970D0 (en) Antibodies
IL273529A (en) Anti-PACAP antibody
IL271067A (en) Anti-trkb antibodies
IL260083B1 (en) Antibody against myl9
PT3456736T (pt) Variantes de anticorpos
ZA202001830B (en) Antibody variants
IL272951A (en) antibody variants
GB201711785D0 (en) Antibodies
GB201709592D0 (en) Antibody
GB201717006D0 (en) Anti-OPG antibodies
HK40015837A (en) Cysteine peptide-enabled antibodies
GB201709818D0 (en) Antibodies
GB201703071D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)